慢性肾脏病患者中钠-葡萄糖协同转运蛋白-2抑制剂的骨折风险
在加拿大安大略省2015至2019年的基于人群的队列研究中,比较新使用SGLT2抑制剂与DPP-4抑制剂的老年人(≥66岁)骨折发生率。经倾向评分逆概率加权后,SGLT2抑制剂组与DPP-4抑制剂组的180天和365天脆性骨折风险无显著差异,且骨折风险与eGFR分类无交互作用。
要点
- 在≥66岁老年人中,新使用SGLT2抑制剂对比DPP-4抑制剂,180天和365天脆性骨折风险无显著差异。
- 按eGFR分类(≥90、60至<90、45至<60、30至<45 ml/min per 1.73 m2)的预设亚组分析未观察到骨折风险与eGFR分类的交互作用(P=0.53)。
- SGLT2抑制剂组加权180天风险HR 0.95(95%CI 0.79至1.13),365天HR 0.88(95%CI 0.88至1.00)。
核心结论
- 在老年人队列中,起始SGLT2抑制剂对比DPP-4抑制剂与骨骼骨折风险升高无关,无论eGFR分类如何。
研究设计与样本
- 2015年至2019年在加拿大安大略省开展的基于人群的队列研究,使用关联的省级行政数据。
- 比较新使用SGLT2抑制剂与新使用DPP-4抑制剂的老年人(≥66岁)的骨折发生率。
- 使用基于倾向评分的逆概率治疗加权平衡两组基线健康指标。
- 比较两组180天和365天骨折累积发生率,并按eGFR分类(≥90、60至<90、45至<60、30至<45 ml/min per 1.73 m2)进行预设亚组分析。
- 加权风险比通过Cox比例风险回归获得。
主要发现
- 加权后,SGLT2抑制剂新使用者共38,994例,DPP-4抑制剂新使用者共37,449例;180天观察到342例骨折,365天观察到689例骨折。
- SGLT2抑制剂对比DPP-4抑制剂的加权180天脆性骨折风险无显著差异:加权HR 0.95(95%CI 0.79至1.13)。
- SGLT2抑制剂对比DPP-4抑制剂的加权365天脆性骨折风险无显著差异:加权HR 0.88(95%CI 0.88至1.00)。
- 未观察到骨折风险与eGFR分类之间的交互作用(P=0.53)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been associated with a higher risk of skeletal fractures in some randomized, placebo-controlled trials. Secondary hyperparathyroidism and increased bone turnover (also common in CKD) may contribute to the observed fracture risk. We aimed to determine if SGLT2 inhibitor use associates with a higher risk of fractures compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, which have no known association with fracture risk. We hypothesized that this risk, if present, would be greatest in patients with lower eGFR. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a population-based cohort study in Ontario, Canada between 2015 and 2019 using linked provincial administrative data to compare the incidence of fracture between new users of SGLT2 inhibitors and DPP-4 inhibitors. We used inverse probability of treatment weighting on the basis of propensity scores to balance the two groups of older adults (≥66 years of age) on indicators of baseline health. We compared the 180- and 365-day cumulative incidence rates of fracture between groups. Prespecified subgroup analyses were conducted by eGFR category (≥90, 60 to <90, 45 to <60, and 30 to <45 ml/min per 1.73 m2). Weighted hazard ratios were obtained using Cox proportional hazard regression. RESULTS: After weighting, we identified a total of 38,994 new users of a SGLT2 inhibitor and 37,449 new users of a DPP-4 inhibitor and observed a total of 342 fractures at 180 days and 689 fractures at 365 days. The weighted 180- and 365-day risks of a fragility fracture did not significantly differ between new users of a SGLT2 inhibitor versus a DPP-4 inhibitor: weighted hazard ratio, 0.95 (95% confidence interval, 0.79 to 1.13) and weighted hazard ratio, 0.88 (95% confidence interval, 0.88 to 1.00), respectively. There was no observed interaction between fracture risk and eGFR category (P=0.53). CONCLUSIONS: In this cohort study of older adults, starting a SGLT2 inhibitor versus DPP-4 inhibitor was not associated with a higher risk of skeletal fracture, regardless of eGFR.
引用
- Cowan A, Jeyakumar N, Kang Y, et al. Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease. Clin J Am Soc Nephrol. 2022. PMID: 35618342. doi:10.2215/CJN.16171221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。